entertainment -WSS

entertainment

author：focus 2025-09-28 21:58:47 - browse：52672

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Medicare inequities exacerbate Puerto Rico’s health disparities

WSS

Medicare solvency divides Republicans at the presidential debate

Diversify hospital leadership teams to protect BIPOC patient health

R1 RCM gets $5.8 billion buyout offer from private equity firm

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Obesity drugs seen as possible treatment for liver disease MASH

In utero gene editing: an explainer

hotspot

entertainment

knowledge

Sports medicine is finally prioritizing gender equality

Diversify hospital leadership teams to protect BIPOC patient health

Activists slam private health insurers over coverage restrictions

In utero gene editing: an explainer

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

A clever new way to fix Medicaid and graduate medical education

Novavax promises a turnaround & Lilly roils the obesity market

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Psychedelics group wrestles with new pharma identity

Alabama IVF ruling threatens families facing fatal genetic disease

Wikipedia

Medicare solvency divides Republicans at the presidential debate

STAT Executive Editor Rick Berke on STAT's 8th birthday

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Sanofi CEO defends move to abandon profit guidance, boost research

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

FDA approves potent Eli Lilly obesity drug, Zepbound

explore

hotspot

hotspot

hotspot